Reform Alaska Native Corporations

June 2 -3, 2026

17th ACI Summit on Biosimilars & Innovator Biologics

Axinn partners Rebecca Clegg and Matt Murphy will speak at American Conference Institute’s Summit on Biosimilars & Innovator Biologics, being held June 2-3 in New York.

Speaking Engagement

Intellectual Property

May 28-29, 2026

20th Annual IBA Competition Mid-Year Conference

On May 29, Axinn partner Bradley Justus will speak on a panel entitled, “Digital economy enforcement with a focus on data and AI" at the International Bar Association’s Competition Mid-Year Conference, being held May 28-29 in Amsterdam.

Speaking Engagement

Antitrust

May 13-14, 2026

Informa CompLaw Antitrust West Coast Conference 2026

Axinn partners Daniel Bitton and Katrina Rouse will speak at Informa’s CompLaw Antitrust West Coast Conference, being held May 13-14 in San Francisco. Daniel will also serve as conference chair.

Speaking Engagement

Antitrust

May 12-13, 2026

ABA 2026 International Law Section Annual Conference

On May 12, Axinn counsel Laura Onken will speak on the “Walking the Tightrope: AI, Blurred Autonomy, and the Future of Competition, Regulation, and IP (CLE)" panel at the ABA 2026 International Law Section Annual Conference held in Washington, DC.

Speaking Engagement

Antitrust

May 7, 2026

I litigated the JetBlue-Spirit merger. A few thoughts on the future of antitrust in the airline industry

Axinn partner Jimmy Moore authored the Fortune article, “I litigated the JetBlue-Spirit merger. A few thoughts on the future of antitrust in the airline industry."

Byline Articles

Antitrust

May 6-7, 2026

2026 FDLI Annual Conference

On May 6, Axinn partner Aziz Burgy will speak on the panel “Do You Copy? Biosimilars, Generics, Fast Tracks and Fine Prints” at the 2026 FDLI Annual Conference, taking place May 6-7 in Washington, DC, and virtually.

Speaking Engagement

Intellectual Property

May 5, 2026

Let's Talk "About". . . That Bird?

Much ink has been spilled over the meaning of “about” when used to characterize an amount or a range recited in a patent claim. Sometimes...

Axinn Viewpoints

Intellectual Property

May 5, 2026

What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions

On April 13-15, Axinn partners Lisl Dunlop and Leslie Overton and counsel Carol Liu attended the Health Care Transactions Conference...

Axinn Viewpoints

Antitrust

April 28, 2026

Seven Axinn Attorneys Named to 2025 Capital Pro Bono Honor Roll

In 2011, the D.C. Courts established the Capital Pro Bono Honor Roll, which annually recognizes members of the D.C. Bar who perform 50 hours or more of pro bono legal services, and additionally recognizes those who perform over 100 hours with a “High Honors” distinction. Axinn is pleased to announce that seven Axinn attorneys have been named to the 2025 Capital Pro Bono Honor Roll:

Pro Bono

Antitrust

April 27, 2026

Axinn Advises Thermo Fisher Scientific on $1.075 Billion Sale of its Microbiology Business to Astorg

Axinn advised Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, on its definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately $1.075 billion. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing.

Deals & Cases

Antitrust

April 27, 2026

Axinn Appoints Rachael Philbin as Chief Innovation Officer

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the Firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the Firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices.

News

April 27, 2026

Teva v. Lilly -- Clarifies Written Description of Method Claims Involving A Genus

The Federal Circuit recently clarified its written description jurisprudence concerning claims directed to methods of using a genus. Teva...

Axinn Viewpoints

Intellectual Property

Inching Toward Balance: Reaching Proper Reform of the Alaska Native Corporations

Related People

Related Services

Featured Insights

Featured Insights